# SineuGene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sineugene

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.sineugene.com
- Latest round: Series A (Mar 31, 2023)
- Investors on record: 3

## About

Established in 2021 and based in Beijing, China, SineuGene operates as a neural evaluation system developer that focuses on gene therapy for nervous system diseases. The co-founder and Chairman of the Scientific Advisory Board, Hechang Jia, is the Dean's Appointed Professor of Medicine at Tsinghua University. The CEO, Peng Lin, was the General Manager of Nanjing Tianyin Health Development. In August 2024, it raised approximately CNY 100 million in a round of pre-series A+ funding.

The company develops gene therapy drugs for neurological diseases, establishes a platform for novel knock-in animal disease models such as Drosophila, mice, and parmesan pigs, and develops therapeutic approaches targeting neurological diseases such as amyotrophic lateral sclerosis, stroke, and Parkinson's disease. The specific drug development pipeline includes SG001, SG002, etc., which have entered the clinical trial stage and obtained ALS indications.

The company generates revenue by developing therapeutic drugs for neurological disorders such as amyotrophic lateral sclerosis, stroke, and Parkinson's disease.

The company will use the pre-series A+ funding raised in August 2024 to advance the IND filing for the first pipeline, SNUG01, and the development of other pipeline products.

## Funding rounds

- Series A, Mar 31, 2023 — MSA Capital, Tsinghua Capital, FC Innovation Venture Fund

## Investors

- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series A
- Tsinghua Capital — Series A
- FC Innovation Venture Fund (https://capitalatlas.ai/funds/fc-innovation-venture-fund) — Series A